Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
- Conditions
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Jason Robert Gotlib
- Target Recruit Count
- 2
- Registration Number
- NCT01034592
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 51
- Registration Number
- NCT01032291
- Locations
- 🇧🇪
ULB Erasme Service de Gastroenterologie, Brussels, Belgium
🇮🇹Azienda Osperdaliero Universitaria Riuniti Umberto I-GM Lancisi-G. Salesi di Ancona Clinica di Oncologia Medica, Ancona, Italy
🇧🇪Grand hôpital de Charleroi, Oncologie, Charleroi, Belgium
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 239
- Registration Number
- NCT01029262
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
🇺🇸Southern Illinois Hematology Oncology, Centralia, Illinois, United States
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
- Conditions
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 9
- Registration Number
- NCT01021423
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT01016600
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01011894
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 5
- Registration Number
- NCT01003769
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT01002755
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Sutter Medical Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT00996931
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1059
- Registration Number
- NCT00988208
- Locations
- 🇺🇸
Cookeville Regional Medical Center, Cookeville, Tennessee, United States
🇺🇸Veterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States
🇦🇹Medizinische Universitat Wien, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.